No Benefit from Carotid Intervention in Fatal Stroke Prevention for >80-Year-old Patients  by De Rango, P. et al.
at SciVerse ScienceDirect
European Journal of Vascular and Endovascular Surgery 44 (2012) 252e259Contents lists availableEuropean Journal of Vascular and Endovascular Surgery
journal homepage: www.ejves.comNo Beneﬁt from Carotid Intervention in Fatal Stroke Prevention for >80-Year-old
Patients
P. De Rango a,*, M. Lenti a, G. Simonte a, E. Cieri a, G. Giordano a, V. Caso c, G. Isernia a, P. Cao b
aDivision of Vascular and Endovascular Surgery, Hospital S.M. Misericordia, Loc. S. Andrea delle Fratte, 06134 Perugia, Italy
bVascular Surgery, Hospital S. Camillo-Forlanini, Rome, Italy
c Stroke Unit, Department of Internal Medicine, Hospital S.M. Misericordia, Perugia, Italy
WHAT THIS PAPER ADDS
 This study questions the beneﬁt of offering carotid interventions to octogenarians, especially in females and asymptomatic patients.
There is an urgent need for high-quality studies to address this issue as evidence suggests that a relatively large number of
octogenarians currently undergo prophylactic carotid interventions on the unproven assumption that they will confer signiﬁcant
beneﬁt.a r t i c l e i n f o
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Background: Invasive management of patients 80 years of age with carotid stenosis may be question-
able. The higher likelihood of stroke needs to be balanced with the increased perioperative risk and the
reduced life expectancy of this ageing population. The purpose of this study was to evaluate the clinical
relevance of carotid stenosis revascularisation in octogenarians.
Methods: All patients80 years of agewho received carotid revascularisation in 2001e2010were reviewed
for perioperative and 5-year outcomes. The experience was comprehensive of carotid endarterectomy
(CEA) and carotid stenting (CAS) performed during the training framewhen agewas not a contraindication
for this procedure. Mortality rates were compared to those of octogenarians of the same geographical
territory according to all-cause and stroke-related mortality national statistics datasets.
Results: A total of 348 procedures performed in 80-year-old patients (272 males) were reviewed: 162
(46.6%) were by CAS and 169 (48.6%) were for symptomatic disease. Perioperative stroke/death rate was
5.5% and was non-signiﬁcantly higher for symptomatic disease (7.1% vs. 3.9% asymptomatic; p ¼ 0.24),
after CAS (6.2% vs. 4.8% CEA; p ¼ 0.64) and in females (6.6% vs. 5.1% males; p ¼ 0.57). At median follow-up
of 36.18 months, 95 deaths and 21 new ischaemic strokes (12 fatal) occurred with 5-year KaplaneMeier
freedom from stroke of 84.8% (78.7%, symptomatic vs. 90.3% asymptomatic; p ¼ 0.003). According to
national datasets, in 80e85-year-old resident population 5-year mortality was 29.9% (23.4% females,
40.6% males) and ischaemic stroke-related mortality was 14.9% (16.8% females, 13.0% males). Corre-
sponding ﬁgures from treated population showed a 5-year mortality of 49.4%, higher in males (39.5%
females, 52.5% males) and ischaemic stroke-related mortality of 20.2%, higher in females (40.0% females,
15.6% males). Comparing data from the study population with residents’ ﬁgures, ischaemic stroke-related
mortality hazard was signiﬁcantly higher in the study females: odds ratio (OR) 3.2, 95% conﬁdence
interval (CI) 1.16e9.17; p ¼ 0.029 (for males: OR 0.97, 95%CI 0.89e1.10; p ¼ 0.99).
Conclusions: Despite perioperative stroke/death risks being lower compared with CAS, the beneﬁt of
surgical carotid revascularisation in old patients remains controversial due to limited life expectancy and
high fatality of stroke in this ageingpopulation. Invasive treatment of carotid stenosismaynot bewarranted
in most patients 80 years of age with carotid stenosis, especially when female and asymptomatic.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.stions on this paper, please go to www.vasculareducation.com and click on ‘CME’
x: þ39 075 5786435.
@unipg.it (P. De Rango).
ciety for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Age is the main non-modiﬁable risk factor for stroke and
mortality. The occurrence of both ischaemic stroke and intracere-
following a standardised protocol in an endovascular suite. Patients
received aspirin (100e325 mg once daily) and clopidogrel (75 mgP. De Rango et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 252e259 253bral haemorrhage doubles in each successive decade after the age
of 55 with ﬁrst-stroke rates particularly high in men 75 years of age
or older.1e5
Age is also known to be the strongest predictor of carotid disease
in both the general healthy population and patients suffering from
acute ischaemic stroke.6,7 Carotid stenosis is a major well-
documented modiﬁable risk factor for stroke and the use of
surgical therapy has been shown to be the best option to reduce the
risk of carotid-related stroke and the associated fatality.1,5 Never-
theless, management of very old patients with carotid stenosis is
challenging: the higher likelihoodof stroke in advanced ages (stroke
incidence accounts for 13.5/1000 persons 75e85 years old and of
32.1/1000persons inmen85 years or older)4,5 and in thepresence of
carotid stenosis7 needs to be balanced with the reduced life expec-
tancy and the increased perioperative risk, especiallymortality, if an
intervention is applied to carotid disease in this ageing pop-
ulation.8e10 Literature data are limited since most octogenarians
have been excluded fromrandomised clinical trials (RCTs) on carotid
treatment and much of the published data on octogenarians and
carotid surgery are provided from single-centre experiences with
limited numbers and conﬂicting results. Comparisons of outcomes
with octogenarians not receiving invasive treatment are lacking and
the clinical relevance of invasive treatment remains questionable
since we do not know how many old patients need to be treated
(NNT) to prevent one stroke event in this age group.
The aim of this study was to analyse early and long-term (5
years) outcome of patients 80 years of age invasively treated for
carotid stenosis and to compare mortality data to octogenarians in
the same geographical territory.Methods
Study population
Consecutive patients with severe carotid stenosis entered into
a prospective electronic database of extracranial carotid revascu-
larisations from January 2001 to February 2010 were reviewed.
For the purpose of the study, all patients 80 years of age or older
were selected. Thereby, the experience was comprehensive of
carotid endarterectomies (CEAs) but also carotid stenting (CAS)
procedures performed during the early time frame (learning curve)
when the procedure was not considered contraindication as it was
since 2005 also due to the diffusion of Carotid Revascularization
Endarterectomy versus Stenting Trial (CREST) lead-in data.11,12
Indications for CAS versus CEA with multiple specialists’ advice
(stroke neurologists, interventional radiologists and vascular
surgeons) were discussed in meetings where details of the proce-
dure were deﬁned by the surgical team. Usually, patients with
unfavourable aortic arch anatomy, severe peripheral vascular
disease precluding femoral access, extremely tortuous carotid
anatomy, allergies to aspirin, clopidogrel or contrast media and
renal insufﬁciency were excluded from CAS. High-neck carotid
bifurcation, obesity and ongoing double anti-platelet were relative
contraindications for CEA. In the last few years, >80-year-old
patients were excluded from CAS and the indications for asymp-
tomatic disease decreased.
Written consent was obtained from all patients before any
revascularisation.
CAS procedure
All CASs were performed with cerebral protection (distal ﬁlter
and selectively proximal occlusion) under local anaesthesiaonce daily with 300 mg loading dose) or ticlopidine (250 mg twice
daily) before the procedure. Post-procedure anti-platelet therapy
included dual drug treatment (aspirin and thienopyridines) for
a minimum of 1 month and continued at the discretion of the
treating physician.
CEA procedure
CEA was performed under local or general anaesthesia. Patients
were under anti-platelet one-drug therapy, either aspirin
(100e325 mg once daily) or thienopyridine (ticlopidine 250 mg
twice daily or clopidogrel 75 mg daily). Shunts were used selec-
tively based on clamping intolerance according to transcranial
Doppler changes or stump pressure measurement when under
general anaesthesia. Eversion or patch and occasionally direct
primary closure were used as arterial closure techniques.
Patient evaluation
Neurological symptomswereevaluatedbya teamofneurologists
who documented the presence, the type and severity (National
Institute of Health (NIH) Stroke Scale) of the event. Patients were
deﬁned as symptomatic when ipsilateral hemispheric or retinal
symptoms occurred within 6 months from the procedure.
Outpatient clinical and ultrasound examinations were sched-
uled at regular intervals after carotid treatment (6 and 12 months
and yearly thereafter).
Outcome measures
Primary end points were mortality and perioperative (30-day)
stroke/death. Secondary end points included ischaemic stroke-
related mortality and freedom from stroke (any perioperative and
late ischaemic). Haemorrhage strokes, after perioperative period,
were excluded.
Local population
Area of investigation
Mortality rates in treated octogenarians were compared to rates
in octogenarians from the local population. The risk of stroke-
related mortality in people with carotid stenosis is higher than in
those without; however, it could be assumed that after effective
intervention on carotid stenosis (CEA or CAS) this risk-excess
should have decreased, approaching that of the general population.
Given a mean age of 82.3 years in the treated population, the
local population for comparison included all residents of 80e85
years of age in the Umbria region. This territory, located in
central Italy, has an area of 8456 km2 (2.8% of the national territory)
(Fig. 1). The resident population was 870,422 (420,933 males and
449,489 females); 59,430 (6.82%) were 80 years of age or older
(20,853 males and 38,577 females), and 34,412 (3.95%) were in the
80e85-year range (12,966 males; 21,446 females). The last was the
population used for control group.
Ascertainment of cases
Data on residents and mortality according to age and gender as
of 31 December 2008 were obtained from the Registry of Nomi-
native Causes of Mortality (ReNCaM) of the Epidemiology and
Statistical Ofﬁce of the Umbria region, Department of Hygiene,
University of Perugia, Perugia, Italy. Deaths and stroke-deaths were
based on the National Institute of STATistic (ISTAT) codes and dis-
played by age, gender and geographical territory over each 5-year
period.
For this study, the local ReNCaM datasets of the last 5-year
period (2004e2008) for the Umbria region were analysed,
Figure 1. Diagrammatic map of the Umbria region in relation to Italy. In the right box: 5-year mortality and stroke-mortality in Umbria 80e85 y population and octogenarian study
population.
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disease e occlusive cerebral vessel disease’. Deaths codiﬁed as
‘cerebral haemorrhage’ were excluded.
Statistical analysis
Data are shown as frequencies and percentages for categorical
variables and mean (SD) or median and interquartile range (IQR),
when required, for continuous variables.
In the treated population, analyses of perioperative and late
outcomes were stratiﬁed by preoperative symptoms, gender and
procedure to account for evident differences in distribution of
patients. Rates of end points at 5 years were estimated with the
KaplaneMeier (KeM) method to compensate for patient dropouts
and the level of signiﬁcance was calculated with log-rank test and
its standard error (SE). Curves were displayed up to a value of
SE < 0.10. To account for event rates in patients receiving bilateral
procedure, at the time of the index event, only one procedure forTable 1
Baseline characteristics in 348 CAS/CEA in >80 year old patients.
Total CAS
N
348
% N
162
Age, y (mean  SD) 82.3  2.4 82.2  2.3
Males 272 78.2 129
Females 76 21.8 33
Symptomatic 169 48.6 70
Peripheral arterial
disease
72 20.7 31
Diabetes 51 14.7 18
Atrial ﬁbrillation 23 6.6 11
Ischaemic heart
disease
109 31.3 55
Hypertension 286 82.2 127
Hyperlipemia 95 27.3 44
CAS ¼ Carotid stenting; CEA ¼ Carotid endarterectomy; MI ¼ Myocardial infarction.each patient was considered and the other was censored at the
same time point. This allowed to account for the double perioper-
ative exposure included in the cumulative event rate analysis for
these patients.
For comparisons between the study population and the local
population of similar age in the Umbria region, absolute event rates
(number of events/number of population at risk) were used in
reporting mortality and stroke-related mortality to allow
measurements of data in the study population comparable to those
calculated by the ISTAT for the local population. Females and males
were analysed separately. Data were analysed per patient (only the
ﬁrst intervention for patients with bilateral procedure was
included).
Data were shown as odds ratio (OR) and correspondent 95%
conﬁdence interval (CI).
SPSS (PCversion Statistical Package for Social Sciences,16.00Win
package, SPSS, Inc., Chicago, IL, USA) was used for data analyses.CEA P value
% N
186
%
82.4  2.5 0.44
79.6 143 76.9 0.60
20.4 43 23.1 0.60
43.2 99 53.2 0.07
19.1 41 22.0 0.60
11.1 33 17.7 0.10
6.8 12 6.5 1.00
34.0 54 29.0 0.35
78.4 159 85.5 0.09
27.2 51 27.4 0.96
Table 2
Medical therapya in 348 CAS/CEA in >80 year old patients.
N %
Statin 121 34.8
Atorvastatin 46 38.3
Pravastatin 9 7.4
Fluvastatin 2 1.7
Rosuvastatin 19 15.8
Simvastatin 44 36.4
Aspirin 248 71.3
Clopidogrel 44 12.6
Ticlopidine 53 15.2
Warfarin 14 4.0
No antiplatelet/anticoagulant 32 9.2
CAS ¼ Carotid stenting; CEA ¼ Carotid endarterectomy.
a One or more.
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Over the study period (2001e2010) 348 carotid procedures
were performed in 323 patients with 80 years of age (mean age
82.3  2.4 years, range 80e91 years; n ¼ 272 males). There were
162 (46.6%) CAS and 186 (53.4%) CEA. Indication for revascularisa-
tionwas symptomatic carotid stenosis in 169 (48.6%). Demographic
and baseline characteristics by procedure and medical therapy are
displayed in Tables 1 and 2. Males and females shared similar
characteristics with the exception of higher rate of peripheral
vascular disease in women (23.9% vs. 9.2% in men; p ¼ 0.004).
The 30-day (periprocedural) risk of stroke/death was 5.5% (19 of
348). Stroke risk was 4.3% (n ¼ 15) and 10 (2.8%) periprocedural
strokes were disabling (Rankin score 3).
Primary periprocedural end-point incidencewas 6.6% in females
versus 5.1% in males, 7.1% in symptomatic versus 3.9% in asymp-
tomatic patients and 6.2% after CAS versus 4.8% after CEA but there
were no signiﬁcant differences in rates (Table 3). In symptomatic
octogenarians the incidence of perioperative primary end point
(stroke/death) was 10.0% after CAS and 5.1% after CEA. In asymp-
tomatic octogenarians, the rate was 3.3% after CAS and 4.6% after
CEA.
Other periprocedural complications by different subgroups are
shown in Table 3. No difference resulted of statistical relevance.
Four myocardial infarctions (MIs), two fatal, occurred. There were
overall eight periprocedural deaths (four stroke and four cardiac
related). Stroke rate was three times (6.5% vs. 2.2%) and disabling
stroke two times (4.1% vs. 1.7%) higher in symptomatic patients but
without statistical signiﬁcance in difference rates when comparedTable 3
Periprocedural (30-day) outcome by subgroup analyses in 348 CAS/CEA in >80 year
old patients.
Stroke/death Stroke Death Disabling
strokea
MI
Overall (N 348) 19 (5.5%) 15 (4.3%) 8 (2.3%) 10 (2.8%) 4 (1.2%)
Males (N 272) 14 (5.12%) 11 (4.0%) 6 (2.2%) 7 (2.6%) 2 (0.7%)
Females (N 76) 5 (6.6%) 4 (5.3%) 2 (2.6%) 3 (3.9%) 2 (2.6%)
P value 0.57 0.75 0.68 0.69 0.2
Symptomatic
(N 169)
12 (7.1%) 11 (6.5%) 4 (2.4%) 7 (4.1%) e
Asymptomatic
(N 179)
7 (3.9%) 4 (2.2%) 4 (2.2%) 3 (1.7%) 4 (2.2%)
P value 0.24 0.06 1.00 0.20 0.12
CAS (N 162) 10 (6.2%) 10 (6.2%) 1 (0.6%) 7 (4.3%) 1 (0.6%)
CEA (N 186) 9 (4.8%) 5 (2.7%) 7 (3.8%) 3 (1.6%) 3 (1.6%)
P value 0.64 0.12 0.07 0.19 0.62
CAS ¼ Carotid stenting; CEA ¼ Carotid endarterectomy; MI ¼Myocardial infarction.
a Rankin score 3.to asymptomatic. Death and cardiac complications were more
similarly distributed (Table 3).
Median follow-up was 36.18 months (IQR 20.9e50.3 months).
No patient was lost. During the observation period, 87 patients died
for an overall (including perioperative) of 95 deaths (18 females, 77
males). Causes of late deaths included stroke (14), cardiac events
(17), cancer (18), respiratory failure (10) andmiscellaneous (suicide,
trauma, renal failure, etc.) reasons (13). Fifteen deaths remained
undeﬁned.
A total of 39 strokes (14 females, 25 males) occurred; 21 were
ischaemic late (after the perioperative period). Sixteen strokes (12
late) were fatal and occurred in six females and 10 males. Three
cerebral haemorrhages (two fatal) were additionally recorded.
The overall KeM survival rate at 5 years from all-cause mortality
was 65.4% (Fig. 2a). Survival rates were not signiﬁcantly higher in
females (73.7% vs. 62.9% in males, p ¼ 0.13) (Fig. 2b) and were
similar in symptomatic and asymptomatic patients (62.6% vs.
67.8%; p ¼ 0.23) (Fig. 2c). Survival rates for the CAS and CEA pop-
ulation are shown in Fig. 2d.
The overall KeM freedom from stroke (any perioperative and
late ischaemic) at 5 years was 84.8% (Fig. 3a). Freedom from stroke
tended to be higher in males (86.6% vs. 79.2% in females; p ¼ 0.139)
(Fig. 3b), and signiﬁcantly higher in asymptomatic than in symp-
tomatic patients (90.3% vs. 78.7%; p ¼ 0.003) (Fig. 3c). There were
similar stroke rates after CAS or CEA (Fig. 3d). Excluding perioper-
ative stroke, the KeM freedom from late ischaemic strokes at 5
years was 90.8% in males versus 83.6% in females (p ¼ 0.122) and
signiﬁcantly higher in asymptomatic (92.3% vs. 85.2% in symp-
tomatic, p ¼ 0.031) patients with an overall freedom rate of 89.1%.
Seven treated vessels developed >50% stenosis during follow-
up with similar distribution by sex (four males, three females)
and procedure (two after CAS and ﬁve after CEA). Only one reste-
nosis associated with stroke.
Comparison of mortality with the local octogenarian population
For comparisons with the local population, only treated patients
who had reached a 5-year follow-up or had died were analysed.
There were 160 patients (38 females; 122 males). Five-year all-
cause mortality rate was 49.4% (n ¼ 79/160) and was higher in
males (n ¼ 64; 52.5%) than in females (n ¼ 15; 39.5%). Five-year
ischaemic stroke rate was 19.3% (n ¼ 31/160); 26.3% (n ¼ 10) in
females and 17.2% (n ¼ 21) in males. Five-year stroke-related
mortality rate (rate of fatal strokes with respect to all mortality)
was 20.2% (n ¼ 16/79) and was particularly high in females, 40.0%
(n ¼ 6/15), while in males the rate was 15.6% (n ¼ 10/64) (Fig. 1,
right box).
According to national statistics mortality datasets, for residents
80e85 years of age at 5 years all-cause mortality rate was 29.9%
(10 288/34 412) and was higher (p < 0.0001) in males (40.6%) than
in females (23.4%). Stroke-related mortality rate was 14.9% (1531/
10 268) and was higher in females than males (16.8% vs. 13.0%
p < 0.0001) (Fig. 1, right box).
Comparing data from the study population with these ﬁgures,
all-cause mortality hazard for the study population was OR
2.29,95%CI 1.68e3.12; p ¼ 0.0001 and stroke-related mortality
hazard was OR 1.4,95%CI 0.95e1.18; p ¼ 0.27. Stroke-related
mortality risk was signiﬁcantly higher in the study females: OR
3.2, 95%CI 1.16e9.17; p ¼ 0.029 (for males: OR 0.97, 95%CI
0.89e1.10; p ¼ 0.99).
Discussion
The study failed to show any signiﬁcant effect of carotid revas-
cularisation in providing stroke fatality prevention for patients
Figure 2. KaplaneMeier survival rates from all-cause-mortality in patients 80 years old receiving invasive treatment. Panel a. All cases. Panel b. male versus female; log-rank test,
p ¼ 0.133. Panel c. symptomatic versus asymptomatic; log-rank test p ¼ 0.226. Panel d. CAS versus CEA; log-rank test: p ¼ 0.022. Black curve is the reference for all cases in
subgroups comparison. Curves were displayed up to a value of SE < 0.10.
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ulation, especially with respect to females. Lack of clinical beneﬁt
was found not only after CAS, as suggested in the literature,12e14 but
also after CEA. Many 80-year-old patients with carotid stenosis
cannot beneﬁt from carotid revascularisation due to limited life
expectancy. In females, high ischaemic stroke fatality (40.0% at 5
years) likely occurs, while in most males there is an excess of
mortality (52.5% at 5 years) mainly non-stroke-related (cancer,
respiratory, etc.) preventing net beneﬁt from carotid revascular-
isation. However, our ﬁndings were related to estimates of risks in
the local octogenarian population and might not apply to outside
settings.
This study started when there was no clear indication on the
hazards from CAS in old people (2001); therefore, a number of
octogenarians received this procedure during the early experience
period, an indication no more in use starting from 2005.11 A
number of studies as well as our personal experience during the
training CAS phase have suggested that patient’s age should beconsidered when selecting treatment (CAS vs. CEA) for carotid
stenosis.11e14 Periprocedural risks in our CAS group was strongly
negatively affected by the inclusion of patients treated during this
initial time experience with CAS (learning curve period).11
In this study, a general population group was used to compare
outcomes of the treated group of octogenarians. The latter group
had undoubtedly higher stroke and stroke fatality risk due to the
presence of carotid stenosis. However, outcomes between treat-
ment and control groups were compared after an interventional
treatment for carotid stenosis; should the treatment be effective,
the excess of stroke exposure in the treated group should be
decreased making the ischaemic stroke risk similar to that of the
general population including octogenarians with and without the
stenosis. Nevertheless, this comparison could not solve the main
study question on the true beneﬁt of carotid revascularisation in old
people. This can be addressed only in trials, that are currently
lacking, with a control group of patients >80 years with carotid
stenosis receiving best medical treatment but not revascularisation.
Figure 3. KaplaneMeier estimates of any-stroke (including perioperative) freedom in patients 80 years old receiving invasive treatment. Panel a. All cases. Panel b. male versus
female; log-rank test p ¼ 0.139. Panel c. symptomatic versus asymptomatic; log-rank test p ¼ 0.003. Panel d. CAS versus CEA: log-rank test p ¼ 0.375; Black curve is the reference for
all cases in subgroups comparison. Curves were displayed up to a value of SE < 0.10.
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in old age,14e16 no study analysed long-term outcomes of old
patients undergoing carotid revascularisation compared to
a control group of people with carotid stenosis of the same age
without revascularisation, to assess the true clinical relevance of
beneﬁt after invasive procedure. What we need to know, but we
still we do not know, is the rate of stroke and stroke fatality in
diseased (with carotid stenosis) but untreated old patients.
Without NNT available to clearly prove the efﬁcacy of invasive
treatment versus medical therapy alone, the decision to intervene
on an octogenarian with carotid stenosis is debatable and might be
justiﬁed only in very selected groups with long life expectancy and
higher stroke risk, which are currently unidentiﬁed. Thereby, our
indications for CEA in old patients have been decreased in the last
few years.
Indications for carotid intervention in elderly patients are
particularly challenging for asymptomatic stenoses for which there
is no clear evidence of large beneﬁt.17e20 Nonetheless, in the realworld, carotid procedures continue to be largely applied worldwide
in asymptomatic patients including octogenarians despite the lack
of consistent evidence to support this practice.1,5,18,20 Nearly half of
the study population was represented by patients with asymp-
tomatic carotid disease. Despite the risk of stroke we found at 5
years being particularly low (freedom from stroke 90.3%), the lack
of consistent beneﬁt in comparison to general old population
suggested us to not have provided a true beneﬁt in these patients.
Therefore, we are decreasing application of carotid intervention,
especially in asymptomatic old patients.
Old women are deemed to be at a higher perioperative risk after
CEA but are more likely to experience more severe stroke and
higher stroke disability.1,4,5 In our study the stroke mortality risk
was particularly evident in the women population. The higher
incidence of peripheral disease observed at baseline in our women
compared to men (23.9% vs. 9.2%; p ¼ 0.004) could have had a role
in a more aggressive generalised cardiovascular disease allowing
higher stroke severity with increased fatality rate for females.
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unsettled and ambiguous due to the particular vulnerability of this
age group. As a person ages there is an accumulation of stressors
and lifetime risk factors that combine with multi-organ physio-
logical changes and increases the risk of poor outcomes. This
vulnerability, deﬁned as ‘frailty’, has been suggested as a useful
measure in public health planning.21 The proportion of ‘frail’ older
people in the population is rising in developed countries as a result
of continued improvements in health care, nutrition and disease
prevention.21 Nevertheless, despite this population shift, there is
evidence that today older adults are still systematically under
addressed by health-care programmes. Many pharmaceutical
companies and previous RCTs have preferred a healthy adult pop-
ulation for their trials to ensure the best possible safety and efﬁcacy
results for their product. In our study we found that common drugs
for cardiovascular risk management were largely underused in
older people (Table 2) receiving carotid invasive treatment (e.g.,
only 34.8% statin use; 9.2% no anti-platelet/anticoagulant). Medical
therapy and health care should be intensiﬁed in many countries to
provide the best strategy against stroke in old patients with carotid
stenosis.
It could be anticipated that more in-depth and accurate patient
selection, based on multi-morbidity assessment, might help to
identify selected subgroups of older patients at higher stroke and
lower late mortality risk who may beneﬁt more from carotid
intervention. However, at this time, the issue is unidentiﬁed and
should be addressed in prospective focussed studies.
Limitations
This study compared two heterogeneous groups 80 years of
age. Patients in the study group with carotid stenosis had a higher
likelihood of cardiovascular events with respect to the general
population of the same age (including people with and without
carotid stenosis). However, it could be assumed that an effective
carotid treatment should have decreased the stroke and stroke-
mortality risk in the ﬁrst group approaching levels of the pop-
ulation without carotid stenosis. Nevertheless, our study did not
answer the main study question that can be addressed only in
studies using for comparison old people with carotid stenosis not
receiving invasive carotid treatment.
Second, comparisons were based on absolute rates and
administrative data from local national datasets, with all the
inherent restraints. The generalisation of our ﬁndings may be
limited. Third, we measured mortality and stroke-related
mortality but not stroke incidence (because of lack of accurate
territory datasets reporting on stroke). However, stroke-fatality
rate can be a measure of stroke rate and requires prevention.
Fourth, the small numbers of the study population could have
led to an overestimation of the true risks (especially for stroke
mortality in females). Five, we included the learning curve time
frame of CAS and a number of old patients received this
procedure (with poorer outcomes), an indication that is no more
in practice today. Finally, the study was retrospective non-
randomised with all the related selection biases: we could not
exclude imbalances in the treated population as those due to
heterogeneity in anti-platelet therapy and type of anaesthesia
and we could not provide relevant details such as the delay
from symptomatic presentation and the stroke type and
lateralisation.
Conclusions
The clinical beneﬁt of carotid revascularisation in 80-year-old
patients may be debatable not only after CAS but also after CEA.Despite perioperative risks lower thanwith CAS, after treatment, the
mortality risk from stroke cannot be prevented in many of these
patients and the life expectancy remains limited (due to high cancer/
pulmonary-related mortality) to take advantages from the surgical
procedure. Periproceduralhazards fromCEAmaybehigher in females
who also experience higher stroke severity and stroke fatality rates.
Today, invasive treatment of carotid stenosis for stroke
prevention might not be necessary in many patients 80 years of
age particularly when female (higher hazards from treatment) and
asymptomatic (low stroke exposure without treatment).Funding
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